Search Result

Results for "

complement

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Complement System (72) Akt (3) Apoptosis (3) Autophagy (1) Caspase (1) CD20 (1) CD38 (2) CTLA-4 (1) Deubiquitinase (1) EGFR (1) Endogenous Metabolite (1) ERK (1) Formyl Peptide Receptor (FPR) (1) HIV Protease (1) Immune Checkpoint (1) Interleukin Related (1) Leukotriene Receptor (1) mTOR (2) NF-κB (1) PD-1/PD-L1 (2) PI3K (1) SARS-CoV (4) Small Interfering RNA (siRNA) (1) TGF-β Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (11) Endocrinology (2) Infection (6) Inflammation/Immunology (70) Metabolic Disease (11) Neurological Disease (4)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Aptamers (4) mRNA (1) Antisense Oligonucleotides (2) siRNAs (2)

103

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Complement System

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138281

Complement factor D-IN-2	Complement System	Inflammation/Immunology
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .

HY-128342

Complement C5-IN-1	Complement System	Inflammation/Immunology
Complement C5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (C5). Complement C5-IN-1 interacts with C5 to prevent its cleavage by the C5 convertase and blocks zymosan-induced the membrane-attack complex (MAC) deposition in 50% human whole blood with an IC₅₀ of 0.77 µM .

HY-102034

Complement factor D-IN-1	Complement System	Inflammation/Immunology
Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC₅₀s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.

HY-P1505A

C3a (70-77) (TFA) 1 Publications Verification complement 3a (70-77) (TFA)	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-Y0641

3-Phenoxybenzaldehyde m-Phenoxybenzaldehyde	Complement System	Inflammation/Immunology
3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity .

HY-P2969

Complement factor I	Endogenous Metabolite	Metabolic Disease
Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46) .

HY-P2830

Complement factor D	Others	Others
Complement factor D is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-149278

Complement C1s-IN-1	Complement System	Inflammation/Immunology
Complement C1s-IN-1 is a potent, selective, orally active and cross the blood-brain barrier C1s inhibitor with an IC₅₀ value of 36 nM .

HY-P1505

C3a (70-77) complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-W049802

N-((Allyloxy)carbonyl)-N-methyl-L-alanine	Complement System	Inflammation/Immunology
N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease .

HY-147080

Avacincaptad pegol sodium ARC1905	Complement System	Others
Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. Avacincaptad pegol sodium treats Geographic atrophy (GA) mice .

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation .

HY-138161

JR14a 2 Publications Verification	Complement System	Inflammation/Immunology
JR14a is a potent thiophene antagonist of *human complement* C3a receptor**. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation .

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-147605

Factor B-IN-3	Complement System	Inflammation/Immunology
Factor B-IN-3 (Example 3 target compound) is a potent complement factor B inhibitor. Factor B-IN-3 can be used for the research of diseases related to inflammation and immunity .

HY-P3502B

Zilucoplan (PEG2)	Complement System	Inflammation/Immunology
Zilucoplan (PEG2) is a Zilucoplan (HY-P3502) derivative, where the linker section replaces PEG24 by PEG2. Zilucoplan is a potent complement component 5 (C5) inhibitor .

HY-NP137

NP-PE (Phycoerythrin)	Complement System	Others
NP-PE (Phycoerythrin) is an immune complex. The formation and transport of NP-PE (Phycoerythrin) depends on the complement system, specifically through the complement receptors CR1 and CR2. These receptors are expressed on the surface of B cells and help B cells capture and transport immune complexes. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes .

HY-E70389

Human Kallikrein	Others	Cardiovascular Disease Inflammation/Immunology
Human Kallikrein is a serine protease that can be found in plasma and tissue. Human Kallikrein has the potential for the research of blood pressure, complement activation, and mediation and maintenance of inflammatory responses .

HY-128570

FD-IN-1	Complement System	Inflammation/Immunology
FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC₅₀ of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC₅₀s of 7.7 and 6.5 µM, respectively .

HY-P990025

Empasiprubart ARGX-117	Complement System	Inflammation/Immunology
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .

HY-147606

Factor B-IN-4	Complement System	Inflammation/Immunology
Factor B-IN-4 (Example 13 target compound) is a potent complement factor B inhibitor, with an IC₅₀ of 1 μM. Factor B-IN-4 can be used for the research of diseases related to inflammation and immunity .

HY-147604

Factor B-IN-2	Complement System	Inflammation/Immunology
Factor B-IN-2 (Example 1 target compound) is a potent complement factor B inhibitor, with an IC₅₀ of 1.5 μM. Factor B-IN-2 can be used for the research of diseases related to inflammation and immunity .

HY-147607

Factor B-IN-5	Complement System	Inflammation/Immunology
Factor B-IN-5 (Example 5 target compound) is a potent complement factor B inhibitor, with an IC₅₀ of 1.2 μM. Factor B-IN-5 can be used for the research of diseases related to inflammation and immunity .

HY-P3252A

Pegcetacoplan acetate	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia .

HY-NP0194

C1q Protein (human)	Complement System	Inflammation/Immunology
C1q Protein (human) is a subunit of the complement system. C1q Protein (human) can bind to various ligands from self, non-self, and altered self, and participate in maintaining the balance of the immune system, promoting tissue repair, and defending against pathogens .

HY-P9914

Eculizumab Anti-Human C5, Humanized Antibody	Complement System	Cardiovascular Disease Cancer
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .

HY-148370A

IONIS-FB-LRx sodium RG6299 sodium	Complement System	Others
IONIS-FB-LRx sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-148370

IONIS-FB-LRx RG6299	Complement System	Others
IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .

HY-147297

Pelecopan BCX9930	Complement System	Inflammation/Immunology
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC₅₀ value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P3502

Zilucoplan RA101495; RA3193	Complement System	Inflammation/Immunology
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-P99050

Sutimlimab	Complement System	Cardiovascular Disease Inflammation/Immunology
Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase .

HY-127105

Iptacopan 5+ Cited Publications LNP023	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC₅₀ value of 10 nM. Iptacopan shows direct, reversible, and high-affinity binding to human factor B with a K_D of 7.9 nM. Iptacopan targets the underlying cause of complement 3 glomerulopathy (C3G) .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-148457

Avacincaptad pegol	Complement System	Infection Inflammation/Immunology
Avacincaptad pegol, which is a pegylated aptamer, has garnered significant attention as a C5 complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA) .

HY-N9481

Lipoteichoic acid	Complement System Autophagy mTOR Akt PI3K ERK Interleukin Related	Infection Metabolic Disease Inflammation/Immunology Cancer
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin .

HY-145720

Cemdisiran ALN-CC5	Small Interfering RNA (siRNA) Complement System	Others
Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.

HY-145720A

Cemdisiran sodium ALN-CC5 sodium	Complement System	Others
Cemdisiran sodium is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.

HY-P99965

Crovalimab SKY59; RO7112689	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-P99767

Olendalizumab ALXN1007	Complement System	Infection
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .

HY-P1036

Compstatin 1 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 1 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P99786

Pozelimab REGN3918	Complement System	Metabolic Disease
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-110136

PMX 205	Complement System	Inflammation/Immunology
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.

HY-110136A

PMX 205 Trifluoroacetate Maximum Cited Publications 7 Publications Verification	Complement System	Inflammation/Immunology
PMX 205 Trifluoroacetate is a specific complement C5aR1 isoform antagonist .

HY-17627

Avacopan 1 Publications Verification CCX168	Complement System	Inflammation/Immunology
Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC₅₀ of 0.1 nM.

Cat. No.	Product Name

HY-L026P

Clinical Compound Library Plus

3,189 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.

MCE owns a unique collection of 3,189 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

HY-L022P

FDA-Approved Drug Library Plus

3,415 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,415 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

HY-L035P

Drug Repurposing Compound Library Plus

5,844 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing.

MCE Drug Repurposing Compound Library plus contains 5,844 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.

MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

HY-L021P

Natural Product Library Plus

5,540 compounds

Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. Natural sources may lead to basic research on potential bioactive components for commercial development as lead compounds in drug discovery.

Nature has been a source of medicinal agents for thousands of years, and an impressive number of modern drugs have been isolated from natural sources, many based on their use in traditional medicine. With the development of new molecular targets, there is an increasing demand for novel molecular diversity for screening. Natural products will play a crucial role in meeting this demand through the continued investigation of world’s bio-diversity, much of which remains unexplored.

MCE provides a unique collection of 5,540 natural compounds that contains Saccharides and Glycosides, Phenylpropanoids, Quinones, Flavonoids, Terpenoids and Glycosides, Steroids, Alkaloid, Phenols, Acids and Aldehydes. Natural Product Library Plus, with more powerful screening capability, further complements Natural Product Library (HY-L021) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

HY-L001P

Bioactive Compound Library Plus

25,361 compounds

Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.

MCE owns a unique collection of 25,361 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc.

Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

HY-L036P

Covalent Screening Library Plus

5,665 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 5,665 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Cat. No.	Product Name	Type

HY-NP137

NP-PE (Phycoerythrin)

Native Proteins

NP-PE (Phycoerythrin) is an immune complex. The formation and transport of NP-PE (Phycoerythrin) depends on the complement system, specifically through the complement receptors CR1 and CR2. These receptors are expressed on the surface of B cells and help B cells capture and transport immune complexes. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes .

HY-NP0194

C1q Protein (human)	Native Proteins
C1q Protein (human) is a subunit of the complement system. C1q Protein (human) can bind to various ligands from self, non-self, and altered self, and participate in maintaining the balance of the immune system, promoting tissue repair, and defending against pathogens .

HY-NP004

Cobra Venom Factor CVF	Native Proteins
Cobra venom factor (CVF) is the complement-activating protein from cobra venom. CVF is a three-chain protein that functionally resembles C3b, the activated form of complement component C3. Cobra Venom Factor can be used for the research of the functions of complement in host defense and immune response as well as in the pathogenesis of diseases .

HY-153229

Firefly luciferase mRNA-LNP

Drug Delivery

Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase mRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase mRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .

HY-NP0194A

C1q Protein (Mouse)	Native Proteins
C1q Protein (Mouse) is the subunit of the complement system. C1q Protein (Mouse) recognizes a variety of ligands, and is involved in maintaining immune system balance, promoting tissue repair, and defending against pathogens .

HY-153230

Firefly luciferase circRNA-LNP

Drug Delivery

Firefly luciferase circRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase circRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .

Cat. No.	Product Name	Target	Research Area

HY-P1505A

C3a (70-77) (TFA) 1 Publications Verification complement 3a (70-77) (TFA)	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-P3252A

Pegcetacoplan acetate	Complement System	Inflammation/Immunology
Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia .

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P3502

Zilucoplan RA101495; RA3193	Complement System	Inflammation/Immunology
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .

HY-P1036

Compstatin 1 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 1 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1505

C3a (70-77) complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-W049802

N-((Allyloxy)carbonyl)-N-methyl-L-alanine	Complement System	Inflammation/Immunology
N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease .

HY-P10274

CM05	Peptides	Inflammation/Immunology
CM05 is a bromo-fatty acid. CM05 can be used to modify ornithodoros moubata complement inhibitor (OmCI) and extend the half-life of OmCI .

HY-P5528

2Abz-SLGRKIQIK(Dnp)-NH2	Peptides	Others
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)

HY-P1398

Compstatin control peptide	Peptides	Inflammation/Immunology
Compstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor .

HY-P1398A

Compstatin control peptide TFA	Peptides	Inflammation/Immunology
Compstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor 1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P1345A

TLQP-21 TFA 1 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P3502A

Zilucoplan TFA RA101495 TFA; RA3193 TFA	Complement System	Inflammation/Immunology
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .

HY-P3204

POT-4 1 Publications Verification AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-P4663

Val-Gly-Ser-Glu NSC 350591	Peptides	Cancer
Val-Gly-Ser-Glu (NSC 350591) is an ECF-A tetrapeptide. Val-Gly-Ser-Glu dose-dependently increases the number of human eosinophils, but not neutrophils, rosetting with complement-coated sheep erythrocytes (EAC3b) .

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-P10632

HiBiT tag	Peptides	Others
HiBiT tag is a complimentary peptide (VSGWRLFKKIS), with high affinity for LgBiT. HiBiT tag is fused to the Gβ subunit of the receptor. The complementation of LgBiT and HiBiT facilitates the stabilization of ETR and G protein. HiBiT is attached to a protein of interest (GFP) to quantify transport to the cytosol .

HY-P1121A

WKYMVM-NH2 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase .

HY-P1717

AMY-101 Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate 2 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA 2 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P5506

C5a Receptor agonist, W5Cha	Complement System	Others
C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC₅₀=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

HY-106178

PMX-53 4 Publications Verification 3D53	Complement System	Cardiovascular Disease Inflammation/Immunology Cancer
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC₅₀ of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .

Cat. No.	Product Name	Target	Research Area

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation .

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-P990025

Empasiprubart ARGX-117	Complement System	Inflammation/Immunology
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .

HY-P9914

Eculizumab Anti-Human C5, Humanized Antibody	Complement System	Cardiovascular Disease Cancer
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-P99050

Sutimlimab	Complement System	Cardiovascular Disease Inflammation/Immunology
Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase .

HY-P990378

*Anti-Complement* Factor P/Properdin Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99965

Crovalimab SKY59; RO7112689	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-P99767

Olendalizumab ALXN1007	Complement System	Infection
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .

HY-P99786

Pozelimab REGN3918	Complement System	Metabolic Disease
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-P990377

*Anti-Complement* Factor B Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P990376

*Anti-Complement* C5aR1 Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P9961

Ofatumumab	CD20	Cancer
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes .

HY-P99636

Gavilimomab ABX-CBL	Inhibitory Antibodies	Inflammation/Immunology
Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody that recognizes CD147 on the cell surface and initiates cell killing through complement-mediated lysis. Gavilimomab can be used for the research of graft-versus-host disease (GVHD) .

HY-P990637

NGM-621	Inhibitory Antibodies	Inflammation/Immunology

HY-P99701

Letolizumab BMS-986004	TNF Receptor	Inflammation/Immunology
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .

HY-P99886

Pexelizumab h5G1. 1-SC	Complement System Apoptosis	Cardiovascular Disease Neurological Disease
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .

HY-P990379

Anti-c-RET Antibody	Inhibitory Antibodies	Inflammation/Immunology

HY-P99730

Mezagitamab TAK-079	CD38	Cancer
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

HY-P9968

Nimotuzumab	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P9976

Isatuximab 1 Publications Verification	Apoptosis	Cancer
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .

HY-P990076

Lorukafusp alfa 14.18 mAb; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

HY-P99117

Cadonilimab AK104	PD-1/PD-L1 CTLA-4 Immune Checkpoint	Inflammation/Immunology Cancer
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .

Species:	Human (40) Rhesus Macaque (1) Mouse (17) Bovine (2) Rat (3) Cynomolgus (4) Pig (1)
Tag:	SUMO (1) His (55) Tag Free (6) Myc (1) Fc (7)
Source:	HEK293 (47) E. coli Cell-free (1) P. pastoris (3) Sf9 insect cells (1) E. coli (16)

Cat. No.	Compare	Product Name	Species	Source

HY-P71552

	Complement C3/C3a Protein, Bovine (His-SUMO) C3complement C3; complement C3b alpha' chain; complement C3c alpha' chain fragment 1; complement C3dg fragment; complement C3g fragment; complement C3d fragment; complement C3f fragment; complement C3c alpha' chain fragment 2]	Bovine	E. coli
	Complement C3/C3a proteins play a key role in initiating the complement system, serving as substrates for C3 convertase in both the classical and alternative pathways. Upon activation, C3 undergoes proteolytic cleavage, yielding C3b, which is covalently bound to surface or immune aggregates. Complement C3/C3a Protein, Bovine (His-SUMO) is the recombinant bovine-derived Complement C3/C3a protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

HY-P7695

	Complement C5/C5a Protein, Mouse 4 Publications Verification rMuC5a; complement C5; Hemolytic complement; C5a	Mouse	E. coli
	Complement C5/C5a Protein, Mouse is a recombinant mouse complement component 5a (C5a). C5a is a potent pro-inflammatory mediator and acts as an essential part of the innate immune response.

HY-P7695A

	Complement C5/C5a Protein, Mouse (His) rMuC5a; complement C5; Hemolytic complement; C5a	Mouse	E. coli
	Complement C5/C5a Protein, Mouse is a recombinant mouse complement component 5a (C5a). C5a is a potent pro-inflammatory mediator and acts as an essential part of the innate immune response.

HY-P78595

	Complement C5/C5a Protein, Cynomolgus C5a; complement Component 5a	Cynomolgus	E. coli
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5/C5a Protein, Cynomolgus is the recombinant cynomolgus-derived Complement C5/C5a protein, expressed by E. coli , with tag free. The total length of Complement C5/C5a Protein, Cynomolgus is 74 a.a., with molecular weight of ~11 kDa.

HY-P75332

	Complement C3 Protein, Cynomolgus (HEK293, His) Anaphylatoxin; C3; complement Component C3a	Cynomolgus	HEK293
	Complement C3 proteins play a key role in initiating the complement system through processing by C3 convertase in the classical and alternative pathways. Upon activation, C3b covalently binds to the surface, while C3a (anaphylatoxin produced by proteolysis of C3) mediates local inflammation. Complement C3 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Complement C3 protein, expressed by HEK293 , with C-His labeled tag. The total length of Complement C3 Protein, Cynomolgus (HEK293, His) is 1641 a.a., with molecular weight of ~186.40 kDa.

HY-P74232

	Complement factor H/CFH Protein, Mouse (HEK293, Fc) complement factor H; Protein beta-1-H; CFH	Mouse	HEK293
	Complement factor H (CFH) protein has C3b and heparin-binding activity and plays a multifaceted role in various processes such as organ development, complement activation, and vasculature development. It is present in different cellular compartments and expressed in different structures, including the adrenal gland, bone, central nervous system, humeral cartilage condensation, and metanephros. Complement factor H/CFH Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Complement factor H/CFH protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77540

	Complement C5/C5a Protein, Mouse (Biotinylated) complement C5; Hemolytic complement; C5a	Mouse	E. coli
	Complement C5/C5a Protein activates late complement components to form the membrane attack complex, C5-C9. C5b binds C6, initiating lytic complex assembly. C5a, produced by C5 degradation, acts as an anaphylatoxin, inducing local inflammation. C5a stimulates intracellular calcium release, smooth muscle contraction, vascular permeability, histamine release, and acts as a chemokine, guiding leukocyte migration. Complement C5/C5a Protein, Mouse (Biotinylated) is the recombinant mouse-derived Complement C5/C5a protein, expressed by E. coli, with tag free. The total length of Complement C5/C5a Protein, Mouse (Biotinylated) is 77 a.a., with molecular weight of ~9 KDa.

HY-P71719

	Complement C5a anaphylatoxin Protein, Pig (P.pastoris, His) C5; complement C5a anaphylatoxin	Pig	P. pastoris
	Complement C5/C5a Protein, a component of the complement system, is involved in the immune response and inflammation. It is cleaved to generate C5a, a potent pro-inflammatory mediator. Complement C5/C5a Protein's role in immune regulation and its potential as a therapeutic target make it a promising candidate for the treatment of inflammatory disorders and autoimmune diseases. Complement C5a anaphylatoxin Protein, Pig (P.pastoris, His) is the recombinant pig-derived Complement C5a anaphylatoxin protein, expressed by P. pastoris , with N-His labeled tag.

HY-P703770

	Complement factor I Protein, Mouse (HEK293, His) complement factor I; C3B/C4B inactivator; Cfi	Mouse	HEK293

HY-P703793

	Complement factor I Protein, Human (HEK293, His) complement factor I; C3B/C4B inactivator; CFI	Human	HEK293

HY-P700959

	Complement C5/C5a Protein, Human (His) C5a; complement C5; C5; CPAMD4; ECLZB	Human	E. coli
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5/C5a Protein, Human (His) is the recombinant human-derived Complement C5/C5a protein, expressed by E. coli , with N-His labeled tag. The total length of Complement C5/C5a Protein, Human (His) is 74 a.a., with molecular weight of 13-14 kDa.

HY-P7890

	Complement factor H/CFH Protein, Human (431a.a, HEK293, His) rHucomplement factor H/CFH, His; complement factor H; CFH	Human	HEK293
	Complement factor H/CFH Protein, Human (431a.a, HEK 293, His) is a recombinant complement factor H (CFH) protein with His tag. Human complement factor H, a central complement control protein, is a member of the regulators of complement activation family.

HY-P72137

	Complement Factor B/CFB Protein, Mouse (His) 1 Publications Verification Cfb; Bf; H2-Bfcomplement factor B; EC 3.4.21.47; C3/C5 convertase; complement factor B Ba fragment; complement factor B Bb fragment	Mouse	E. coli
	CFB is an important component of the alternative pathway of the complement system and is cleaved by factor D, producing two fragments: Ba and Bb. The Bb fragment is characterized as a serine protease and subsequently forms a complex with complement factor 3b, ultimately producing a C3 or C5 convertase. Complement Factor B/CFB Protein, Mouse (His) is the recombinant mouse-derived CFB protein, expressed by E. coli , with N-6*His labeled tag. The total length of Complement Factor B/CFB Protein, Mouse (His) is 739 a.a., with molecular weight of ~87 kDa.

HY-P7830

	Complement factor H/CFH Protein, Mouse (HEK293, His) rMucomplement factor H/CFH, His; complement factor H; Protein beta-1-H; CFH	Mouse	HEK293
	Complement factor H (CFH) lacks essential conserved residue(s) for feature annotation propagation. Complement factor H/CFH Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement factor H/CFH protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Complement factor H/CFH Protein, Mouse (HEK293, His) is 378 a.a., with molecular weight of 60-75 kDa.

HY-P7862

	Complement C3/C3a Protein, Human 2 Publications Verification rHucomplement C3/C3a; complement Component C3a; C3a; Anaphylatoxin	Human	E. coli
	Complement C3/C3a protein plays a key role in initiating the complement system through processing by C3 convertase in both the classical and alternative pathways. Complement C3/C3a protein is involved in various immune and inflammatory responses and also has a role in regulating blood pressure. Complement C3/C3a Protein, Human is a recombinant Complement C3/C3a protein expressed in E. coli, untagged, and consists of 77 amino acids (S672-R748).

HY-P7863

	Complement C3/C3a Protein, Mouse 3 Publications Verification rMucomplement C3/C3a; complement Component C3a; Anaphylatoxin; C3a	Mouse	E. coli
	Complement C3/C3a protein activates the complement system, playing a central role in both classical and alternative pathways. C3b binds covalently to cell surface carbohydrates or immune aggregates, while C3a acts as an inflammatory mediator, inducing neutrophil chemoattraction and promoting smooth muscle contraction, increased vascular permeability, and histamine release. The shorter isoform of C3a stimulates B-cells. Complement C3/C3a Protein, Mouse is the recombinant mouse-derived Complement C3/C3a protein, expressed by E. coli , with tag free.

HY-P7864

	Complement C5/C5a Protein, Human rHucomplement C5/C5a; complement C5; C5a anaphylatoxin; C5a	Human	E. coli
	Complement C5/C5a Protein, Human is a recombinant human complement C5a. C5a is a 74-amino acid glycoprotein generated on activation of the C system. Complement C5 is cleaved by proteolysis in the terminal phase of complement activation generating the pro-inflammatory C5a and membrane attack complex nucleator C5b. C5a is an inflammatory mediator generated by complement activation that positively regulates various arms of immune defense, including Toll-like receptor 4 (TLR4) signaling.

HY-P700862

	Complement C5 Protein, Human (HEK293, His) complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D	Human	HEK293
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5 Protein, Human (HEK293, His) is the recombinant human-derived Complement C5 protein, expressed by HEK293 , with C-His labeled tag. The total length of Complement C5 Protein, Human (HEK293, His) is 1658 a.a., with molecular weight of 110-114 kDa (α chain) & 69-73 kDa (β chain), respectively.

HY-P7824

	Complement C8G Protein, Human (His) rHucomplement component C8 gamma chain/C8G, His; complement component C8 gamma chain; C8G	Human	E. coli
	C8G/C8 γ is the γ subunit of the C8 protein of the complement system and is mainly localized in brain astrocytes. C8G/C8 γ is a neuroinflammation inhibitor that interacts with S1PR2 and jointly antagonizes the pro-inflammatory activity of S1P in microglia. Complement C8G Protein, Human (His) is the recombinant human-derived Complement C8G protein, expressed by E. coli , with N-6*His labeled tag. The total length of Complement C8G Protein, Human (His) is 182 a.a., with molecular weight of ~22.0 kDa.

HY-P72946

	Complement factor H/CFH Protein, Human (372a.a, HEK293, His) complement factor H; H factor 1; CFH; HF; HF1; HF2	Human	HEK293
	Complement factor H/CFH proteins regulate complement activation and act as soluble inhibitors to prevent complement amplification on the cell surface. Complement factor H/CFH Protein, Human (372a.a, HEK293, His) is the recombinant human-derived Complement factor H/CFH protein, expressed by HEK293 , with C-His labeled tag.

HY-P7861

	Complement Factor D/Adipsin Protein, Human (HEK293, His) rHucomplement Factor D/Adipsin, His; complement factor D; CFD; Adipsin; C3 convertase activator; Properdin factor D; DF; PFD	Human	HEK293
	Complement factor D, also known as Adipsin, plays a crucial role in the alternative pathway of the complement system and when complexed with factor C3b, it cleaves factor B. This cleavage activates the C3bbb complex, converting it to the C3 convertase of the alternative pathway. Complement Factor D/Adipsin Protein, Human (HEK293, His) is the recombinant human-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-10*His labeled tag. The total length of Complement Factor D/Adipsin Protein, Human (HEK293, His) is 228 a.a., with molecular weight of ~28.0 kDa.

HY-P7824A

	Complement C8G Protein, Human (N-6His) rHucomplement component C8 gamma chain/C8G, His; complement* component C8 gamma chain; C8G	Human	E. coli

HY-P7861A

	Complement Factor D/Adipsin Protein, Human (HEK293, His, Solution) rHucomplement Factor D/Adipsin, His; complement factor D; CFD; Adipsin; C3 convertase activator; Properdin factor D; DF; PFD	Human	HEK293
	Complement factor D, also known as Adipsin, plays a crucial role in the alternative pathway of the complement system and when complexed with factor C3b, it cleaves factor B. This cleavage activates the C3bbb complex, converting it to the C3 convertase of the alternative pathway. Complement Factor D/Adipsin Protein, Human (HEK293, His, Solution) is the recombinant human-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-10*His labeled tag. The total length of Complement Factor D/Adipsin Protein, Human (HEK293, His, Solution) is 228 a.a., with molecular weight of ~28.0 kDa.

HY-P71726

	Complement Factor D/Adipsin Protein, Rat (P.pastoris, His) Cfd; Adn; Df; complement factor D; EC 3.4.21.46; Adipsin; C3 convertase activator; Endogenous vascular elastase; Properdin factor D	Rat	P. pastoris
	Complement Factor D/Adipsin Protein is pivotal, cleaving factor B within the factor C3b complex to activate the C3bbb complex, serving as the C3 convertase in the alternate pathway—analogous to C1s in the classical pathway. Complement Factor D/Adipsin Protein, Rat (P.pastoris, His) is the recombinant rat-derived Complement Factor D/Adipsin protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of Complement Factor D/Adipsin Protein, Rat (P.pastoris, His) is 238 a.a., with molecular weight (glycosylation form) of ~43 kDa.

HY-P7876

	Complement Factor D/Adipsin Protein, Mouse (HEK293, His) rMucomplement Factor D/Adipsin, His; complement factor D; 28 kDa adipocyte protein; Adipsin; C3 convertase activator; Properdin factor D; Cfd; Adn; Df	Mouse	HEK293
	Complement Factor D/Adipsin Protein cleaves factor B in complex with factor C3b, activating the C3bbb complex to form the C3 convertase in the alternate pathway, analogous to C1s in the classical pathway. Complement Factor D/Adipsin Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P78247

	Complement C3 Protein, Mouse (HEK293, His) complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p	Mouse	HEK293
	Complement C3 protein activates the complement system, playing a central role in both classical and alternative pathways. C3b binds covalently to cell surface carbohydrates or immune aggregates, while C3a acts as an inflammatory mediator, inducing neutrophil chemoattraction and promoting smooth muscle contraction, increased vascular permeability, and histamine release. The shorter isoform of C3a stimulates B-cells. Complement C3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement C3 protein, expressed by HEK293 , with C-His labeled tag.

HY-P702819

	Complement C3 Protein, Human (HEK293, His) complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p	Human	HEK293
	Complement C3 protein activates the complement system, playing a central role in both classical and alternative pathways. C3b binds covalently to cell surface carbohydrates or immune aggregates, while C3a acts as an inflammatory mediator, inducing neutrophil chemoattraction and promoting smooth muscle contraction, increased vascular permeability, and histamine release. The shorter isoform of C3a stimulates B-cells. Complement C3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement C3 protein, expressed by HEK293 , with C-His labeled tag. The total length of Complement C3 Protein, Mouse (HEK293, His) is 1639 a.a., with molecular weight of 65-68 kDa & 110-115 kDa & 165-180 kDa, respectively.

HY-P7813

	Complement Factor B/CFB Protein, Human (HEK293, His) rHucomplement Factor B, His; complement Factor B; C3/C5 Convertase; Glycine-Rich Beta Glycoprotein; GBG; PBF2; Properdin Factor B; CFB; BF; BFD	Human	HEK293
	Complement Factor B/CFB Protein, Human (HEK293, His) is the recombinant human-derived Complement Factor B/CFB protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Complement Factor B/CFB Protein, Human (HEK293, His) is 739 a.a., with molecular weight of 90-120 kDa.

HY-P78273

	Complement Factor D/Adipsin Protein, Mouse (HEK293, Fc) Adipsin; C3 convertase activator; complement factor D; CFD; PFD; DF; ADN; FACTOR D; AMBP-1; EC 3.4.21; EC 3.4.21.46	Mouse	HEK293
	Complement Factor D/Adipsin Protein cleaves factor B in complex with factor C3b, activating the C3bbb complex to form the C3 convertase in the alternate pathway, analogous to C1s in the classical pathway. Complement Factor D/Adipsin Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P78545

	Complement Factor D/Adipsin Protein, Human (HEK293, Fc) Adipsin; C3 convertase activator; complement factor D; CFD; PFD; DF; ADN; FACTOR D; AMBP-1; EC 3.4.21; EC 3.4.21.46	Human	HEK293
	Complement factor D, also known as Adipsin, plays a crucial role in the alternative pathway of the complement system and when complexed with factor C3b, it cleaves factor B. This cleavage activates the C3bbb complex, converting it to the C3 convertase of the alternative pathway. Complement Factor D/Adipsin Protein, Human (HEK293, Fc) is the recombinant human-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Complement Factor D/Adipsin Protein, Human (HEK293, Fc) is 228 a.a., with molecular weight of 52-60 kDa.

HY-P77898

	Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, His) Adipsin; C3 convertase activator; complement factor D; CFD; PFD; DF; ADN; FACTOR D; AMBP-1; EC 3.4.21; EC 3.4.21.46	Rhesus Macaque	HEK293
	Complement Factor D/Adipsin Protein is a member of the S1, or chymotrypsin, family of serine peptidases. Complement Factor D is expressed by adipose cells, plays an important role in both physiology and pathophysiology, where it plays a regulatory role in the complement system. Complement Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-His labeled tag. The total length of Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, His) is 233 a.a., with molecular weight of 70-80 kDa.

HY-P74371

	*C7/Complement* component C7 Protein, Human (HEK293, His)** complement component C7; C7	Human	HEK293
	C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, His) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293 , with C-His labeled tag. The total length of C7/Complement component C7 Protein, Human (HEK293, His) is 843 a.a., with molecular weight of 92-98 kDa.

HY-P74372

	*C7/Complement* component C7 Protein, Human (HEK293, Fc)** complement component C7; C7	Human	HEK293
	C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, Fc) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of C7/Complement component C7 Protein, Human (HEK293, Fc) is 843 a.a., with molecular weight of ~118 kDa.

HY-P74373

	*C6/Complement* component C6 Protein, Human (HEK293, His)** complement component C6; C6	Human	HEK293
	C6/Complement component C6 Protein is a part of the lytic membrane attack complex formed during complement activation, which has an indispensable role in innate and acquired immune responses by forming pores in the plasma membrane of target cells, as well as cancer immune surveillance. It is a component of the complement cascade which can be incorporated into the cell membrane and cause cell lysis. People with C6 deficiency are prone to bacterial infection. C6/Complement component C6 Protein, Human (HEK293, His) is the recombinant human-derived C6/Complement component C6 protein, expressed by HEK293 , with C-His labeled tag.

HY-P74374

	*C2/Complement* C2 Protein, Mouse (HEK293, His)** complement C2; C3/C5 convertase; C2	Mouse	HEK293
	Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P74375

	*C2/Complement* C2 Protein, Human (HEK293, His)** complement C2; C3/C5 convertase; C2	Human	HEK293
	C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, His) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag. The total length of C2/Complement C2 Protein, Human (HEK293, His) is 732 a.a., with molecular weight of ~112 kDa.

HY-P74376

	*C2/Complement* C2 Protein, Human (HEK293, Fc)** complement C2; C3/C5 convertase; C2	Human	HEK293
	C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, Fc) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of C2/Complement C2 Protein, Human (HEK293, Fc) is 732 a.a., with molecular weight of 110-130 kDa.

HY-P700696

	*C1s/Complement* component C1s Protein, Human (HEK293, His)** complement C1s subcomponent; C1 esterase	Human	HEK293
	C1s/Complement component C1s, a serine protease and B chain, forms C1 with C1q and C1r, initiating the classical complement pathway. Activated by C1r, C1s then activates downstream components C2 and C4, crucially driving the complement system cascade. C1s/Complement component C1s Protein, Human (HEK293, His) is the recombinant human-derived C1s/Complement component C1s protein, expressed by HEK293, with C-His labeled tag. The total length of C1s/Complement component C1s Protein, Human (HEK293, His) is 673 a.a., with molecular weight of 55-60 kDa (light chain), 32-35 kDa (heavy chain).

HY-P700697

	*C2/Complement* C2 Protein, Cynomolgus (HEK293, His)** complement C2; C3/C5 convertase; C2; ARMD14; CO2	Cynomolgus	HEK293
	Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P70504

	Adiponectin/Acrp30 Protein, Human (HEK293, His) 1 Publications Verification Adiponectin; 30 kDa Adipocyte complement-Related Protein; Adipocyte complement-related 30 kDa protein; ACRP30; Adipocyte; C1q and Collagen Domain-Containing Protein; Adipose Most Abundant Gene Transcript 1 Protein; apM-1; Gelatin-Binding Protein; ADIPOQ; ACDC; ACRP3	Human	HEK293
	Adiponectin/Acrp30 Protein, Human (HEK293, His) could increase cell sensitivity to insulin and can be used as a potential protein for treating diabetic tendinopathy.

HY-P72721

	CD55/DAF Protein, Human (HEK293, His) complement Decay-Accelerating factor; CD55; CR; DAF	Human	HEK293
	The CD55/DAF protein is critical in the immune system, recognizing C4b and C3b fragments, interfering with their enzymatic conversion and preventing the formation of complement cascade amplifying convertase. This regulatory mechanism alleviates complement-induced damage by inhibiting complement activation. CD55/DAF Protein, Human (HEK293, His) is the recombinant human-derived CD55/DAF protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD55/DAF Protein, Human (HEK293, His) is 319 a.a., with molecular weight of 50-75 kDa.

HY-P75394

	CD55/DAF Protein, Human (HEK293, hFc) complement Decay-Accelerating factor; CD55; CR; DAF	Human	HEK293
	The CD55/DAF protein is critical in the immune system, recognizing C4b and C3b fragments, interfering with their enzymatic conversion and preventing the formation of complement cascade amplifying convertase. This regulatory mechanism alleviates complement-induced damage by inhibiting complement activation. CD55/DAF Protein, Human (HEK293, hFc) is the recombinant human-derived CD55/DAF protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD55/DAF Protein, Human (HEK293, hFc) is 319 a.a., with molecular weight of 95-105 kDa.

HY-P75655

	CD55/DAF Protein, Mouse (HEK293, His) complement Decay-Accelerating factor; CD55; CR; DAF	Mouse	HEK293
	The CD55/DAF protein is critical in the immune system and recognizes C4b and C3b fragments. It interacts with cell-associated C4b and C3b, interfering with their enzymatic conversion and preventing the formation of complement cascade amplifying convertase. CD55/DAF Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD55/DAF protein, expressed by HEK293 , with C-His labeled tag.

HY-P76241

	CD55/DAF Protein, Rat (HEK293, Fc) complement Decay-Accelerating factor; CD55; CR; DAF	Rat	HEK293
	The CD55/DAF protein lacks conserved residues critical for feature annotation propagation and exhibits unique qualities that have prompted exploration of its structural and functional implications. This unique property suggests underlying nuances in molecular interactions and regulatory mechanisms. CD55/DAF Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD55/DAF protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75464

	C1QB Protein, Human (sf9, His) complement C1q subcomponent subunit B; C1QB	Human	Sf9 insect cells
	The C1QB protein plays a critical role in the assembly of C1, the initial component of the serum complement system. C1q binds to the zymogens C1r and C1s, resulting in C1 assembly. C1QB Protein, Human (sf9, His) is the recombinant human-derived C1QB protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of C1QB Protein, Human (sf9, His) is 226 a.a., with molecular weight of ~30 kDa.

HY-P7444

	MASP1 Protein, Human (HEK293, His) rHuMannan-binding lectin serine protease 1, His; complement MASP3; MASP-1	Human	HEK293
	MASP1 Protein, Human (HEK293, His) is a recombinant human Mannan-binding lectin serine protease 1 produced in HEK293 cells, with a His tag at the C-terminus. Mannan-binding lectin serine protease 1 is a serine protease associated with humoral pattern-recognition molecules.

HY-P76185

	HABP1/C1QBP Protein, Mouse (His) complement component 1 Q subcomponent-binding protein, mitochondrial; HABP1	Mouse	E. coli
	HABP1/C1QBP Protein, part of the MAM33 family, is associated with a distinct protein family known for unique characteristics and functions. In the MAM33 family, HABP1 likely plays a significant role in associated cellular processes, though specific functions need exploration. Investigating HABP1's functions and implications within the broader MAM33 family will enhance understanding of its unique properties and potential roles in cellular processes, offering insights into its significance within this protein family. HABP1/C1QBP Protein, Mouse (His) is the recombinant mouse-derived HABP1/C1QBP protein, expressed by E. coli, with N-His labeled tag. The total length of HABP1/C1QBP Protein, Mouse (His) is 208 a.a., with molecular weight of ~32 KDa.

HY-P72690

	CFHR4 Protein, Human (HEK293, His) complement factor H-related protein 4; FHR-4; CFHR4; CFHL4	Human	HEK293
	CFHR4, a key regulator of complement, intricately orchestrates the complement system. It associates with lipoproteins, suggesting involvement in lipid metabolism. Operating as a homodimer, CFHR4 plays a crucial role in balancing complement activation and regulation. CFHR4 Protein, Human (HEK293, His) is the recombinant human-derived CFHR4 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P700398

	C5AR1 Protein-VLP, Human (HEK293, His) complement component 5a receptor 1; C5R1, complement component 5 receptor 1 (C5a ligand); C5a anaphylatoxin chemotactic receptor; C5A; C5AR; CD88; C5a-R; C5a ligand; C5a anaphylatoxin receptor; complement component 5 receptor 1; C5R1	Human	HEK293
	C5AR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P72890

	CD21 Protein, Human (HEK293, His) complement receptor type 2; Cr2; EBV receptor; CD21; C3DR	Human	HEK293
	CD21 Protein, a receptor for complement C3, Epstein-Barr virus, and HNRNPU, activates B lymphocytes and aids Epstein-Barr virus entry in microbial infection. Its engagement with these ligands highlights its vital role in immune responses and interactions, regulating B-cell activation and host defense against infections. CD21 Protein, Human (HEK293, His) is the recombinant human-derived CD21 protein, expressed by HEK293 , with C-His, C-10*His labeled tag. The total length of CD21 Protein, Human (HEK293, His) is 951 a.a., with molecular weight of 110-120 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81185

	C5b-9 Antibody C5; C6; C7; C8; C9; complement component 5; complement component 6; complement component 7; complement component 8; complement component 9; MAC; Membrane attack complex; TCC; Terminal complement complex.	WB, IHC-P, IHC-F, ICC/IF	Human, Rat
	C5b-9 Antibody is an unconjugated, rabbit-derived, anti-C5b-9 polyclonal antibody. C5b-9 Antibody can be used for: WB, IHC-P, IHC-F, IF expriments in human, rat, and predicted: mouse background without labeling.

HY-P82695

	CD55 Antibody (YA2440) CD55; CR; DAF; complement decay-accelerating factor; CD55	WB	Human
	CD55 Antibody (YA2440) is a biotin-conjugated non-conjugated IgG antibody, targeting CD55, with a predicted molecular weight of 41 kDa (observed band size: 78 kDa). CD55 Antibody (YA2440) can be used for WB experiment in human background.

HY-P81583

	CD35 Antibody (YA1328) C3BR,complement receptor type 1,C3b/C4b receptor,CD35	IHC-P	Human
	CD35 Antibody (YA1328) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1328), targeting CD35. CD35 Antibody (YA1328) can be used for IHC-P experiment in human background.

HY-P80795

	Phospho-CD18 (Ser745) Antibody ITGB2; CD18; MFI7; Integrin beta-2; Cell surface adhesion glycoproteins LFA-1/CR3/p150; 95 subunit beta; complement receptor C3 subunit beta; CD antigen CD18	WB, IP	Human, Mouse, Rat
	Phospho-CD18 (Ser745) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 85 kDa, targeting to Phospho-CD18 (Ser745). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P83239

	Complement factor B Antibody (YA2984) C3/C5 convertase; complement factor B; PBF2; Properdin factor B	WB	Human
	Complement factor B Antibody (YA2984) is a biotin-conjugated non-conjugated IgG antibody, targeting Complement factor B, with a predicted molecular weight of 86 kDa (observed band size: 100 kDa). Complement factor B Antibody (YA2984) can be used for WB experiment in human background.

HY-P81468

	C1QA Antibody (YA1213) C1qa; complement C1q subcomponent subunit A; complement component 1 q subcomponent A chain; complement component 1 q subcomponent alpha polypeptide	IHC-P	Human
	C1QA Antibody (YA1213) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1213), targeting C1QA. C1QA Antibody (YA1213) can be used for IHC-P experiment in human background.

HY-P80577

	C3 Antibody AHUS5; ARMD9; ASP; complement C3; complement factor 3; CPAMD1; HEL S 62p	WB, IHC-P	Human
	C3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 187 kDa, targeting to C3. It can be used for WB,IHC-P assays with tag free, in the background of Human.

HY-P81889

	C1QB Antibody (YA1634) C1qb; complement component 1 q subcomponent B chain	WB, IHC-P, ICC/IF	Human
	C1QB Antibody (YA1634) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1634), targeting C1QB, with a predicted molecular weight of 27 kDa (observed band size: 27 kDa). C1QB Antibody (YA1634) can be used for WB, IHC-P, ICC/IF experiment in human background.

HY-P81562

	CD21 Antibody (YA1307) C3DR antibody; CD 21 antibody; CD21 antibody; complement C3d receptor antibody; complement component (3d/Epstein Barr virus) receptor 2 antibody; complement receptor type 2 antibody; CR antibody; Cr2 antibody; CR2_HUMAN antibody; CVID7 antibody; EBV receptor antibody; EBV-R antibody; Epstein Barr virus receptor antibody; Epstein-Barr virus receptor antibody; EVBR antibody; SLEB9 antibody	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	CD21 Antibody (YA1307) is a biotin-conjugated non-conjugated IgG antibody, targeting CD21, with a predicted molecular weight of 113 kDa (observed band size: 155 kDa). CD21 Antibody (YA1307) can be used for WB,IF-Cell,IHC-P,FC,IF-Tissue experiment in human, mouse, rat background.

HY-P81760

	C4A Antibody (YA1505) Acidic C4; Acidic complement C4; Basic C4; Basic complement C4; C4A; C4A2; C4A3; C4A4; C4A6; C4AD; C4B1; C4B12; C4B2; C4B3; C4BD; C4F; C4S; CPAMD2; CPAMD3	WB, IHC-P, FC	Human
	C4A Antibody (YA1505) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1505), targeting C4A, with a predicted molecular weight of 193 kDa (observed band size: 193 kDa). C4A Antibody (YA1505) can be used for WB, IHC-P, FC experiment in human background.

HY-P83616

	Factor H Antibody (YA3361) AHUS1; AMBP1; ARMD4; ARMS1; beta1H; CFH; CFHL3; complement factor H; isoform b; Factor H; factor H like 1; FHL1; HF1; HF2; HUS	WB, ICC/IF	Human
	Factor H Antibody (YA3361) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3361), targeting Factor H, with a predicted molecular weight of 139 kDa (observed band size: 180 kDa). Factor H Antibody (YA3361) can be used for WB, ICC/IF experiment in human background.

HY-P81176

	CD11c Antibody Integrin alpha-X; integrin alpha-X precursor; ITGAX; SLEB6; CD11C (p150) alpha polypeptide; complement receptor 4; integrin aX; CD11 antigen-like family member C; leukocyte adhesion receptor p150,95; leukocyte adhesion glycoprotein p150,95 alpha chain; ITAX_HUMAN.	ELISA	Human, Rat
	CD11c Antibody is an unconjugated, approximately 126 kDa, rabbit-derived, anti-CD11c polyclonal antibody. CD11c Antibody can be used for: ELISA, Flow-Cyt, IF expriments in human, rat, and predicted: mouse, dog background without labeling.

HY-P82566

	GC1q R Antibody (YA2311) C1QBP; GC1QBP; HABP1; SF2P32; complement component 1 Q subcomponent-binding protein; mitochondrial; GC1q-R protein; Glycoprotein gC1qBP; C1qBP; Hyaluronan-binding protein 1; Mitochondrial matrix protein p32; p33	WB, IP	Human, Mouse, Rat
	GC1q R Antibody (YA2311) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2311), targeting GC1q R, with a predicted molecular weight of 31 kDa (observed band size: 31 kDa). GC1q R Antibody (YA2311) can be used for WB, IP experiment in human, mouse, rat background.

HY-P80004

	Adiponectin Antibody 30 kDa adipocyte complement related protein; ACDC; ACRP 30; ACRP30; ADIPO_HUMAN; Adipocyte; AdipoQ; Adipose most abundant gene transcript 1; Adipose specific collagen like factor; ADIPQTL1; ADPN; APM 1; apM-1; ApM1; C1q and collagen domain-containing protein; GBP 28; GBP28; Gelatin binding protein; Gelatin binding protein 28; Gelatin-binding protein.	WB, ICC/IF, IHC-P	Mouse
	Adiponectin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 27 kDa, targeting to Adiponectin. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Mouse.